Dextech Medical

Dextech Medical EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Dextech Medical (DEX.SL) as of Oct 15, 2026 is -35.07 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -21.19 % — a change of 65.54% (lower).

EBIT/Assets

-35.07 %

YoY

65.54%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Dextech Medical is 2026 -35.07 % . Operating Income to Assets Ratio (EBIT/Assets) of Dextech Medical was 2025 -21.19 % . It decreases by 65.54% lower compared to the previous year.

The Dextech Medical EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2019
-37.25 SEK
Jan 1, 2020
-57.81 SEK
Jan 1, 2021
-83.98 SEK
Jan 1, 2022
-13.31 SEK
Jan 1, 2023
-14.10 SEK
Jan 1, 2024
-18.14 SEK
Jan 1, 2025
-21.19 SEK
Jan 1, 2026
-35.07 SEK
The Dextech Medical EBIT/Assets history
YEAREBIT/AssetsYoY
-35.07 %+65.54%
-21.19 %+16.79%
-18.14 %+28.66%
-14.10 %+5.93%
-13.31 %-84.15%
-83.98 %+45.28%
-57.81 %+55.18%
-37.25 %-12.24%
-42.44 %+60.26%
-26.48 %-0.44%
-26.60 %+37.21%
-19.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dextech Medical Stock analysis

What does Dextech Medical do? Dextech Medical AB is a biotechnology company based in Uppsala, Sweden, operating within the healthcare sector. The company has a single full-time employee and went public via an IPO on June 19, 2014. Its primary focus is the research and development of drug candidates targeting urological oncology, with specific emphasis on prostate cancer, as well as other cancers and non-malignant diseases. Dextech Medical AB utilizes a technology platform called GuaDex, which is patented, and has developed three drug candidates with associated patents or patent applications. These candidates include OsteoDex, designed for the treatment of bone metastases in castration-resistant prostate cancer; SomaDex, which leverages somatostatin, an endogenous hormone, for the treatment of acromegaly, neuroendocrine tumors, and palliative care for prostate cancer; and CatDex, intended for the instillation treatment of bladder cancer. The company's website is https://dextechmedical.com/. Dextech Medical AB is listed under the ticker DEX.SL with ISIN SE0005881489. The company's operations are centered around developing innovative therapeutic solutions through its proprietary platform, aiming to address significant unmet medical needs in oncology and related fields. Dextech Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dextech Medical stock

Operating Income to Assets Ratio (EBIT/Assets) of Dextech Medical is -35.07 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of Dextech Medical changed from -21.19 % to -35.07 %, representing a 65.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Dextech Medical since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Dextech Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Dextech Medical

All Key Metrics — Dextech Medical